{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T20:58:11Z","timestamp":1768424291463,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.reuma.2012.10.010","type":"journal-article","created":{"date-parts":[[2013,11,8]],"date-time":"2013-11-08T12:46:36Z","timestamp":1383914796000},"page":"201-205","source":"Crossref","is-referenced-by-count":21,"title":["Eficacia y tolerabilidad de rituximab en el tratamiento de pacientes con rhupus"],"prefix":"10.1016","volume":"9","author":[{"given":"Lilia","family":"Andrade-Ortega","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fedra","family":"Irazoque-Palazuelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Mu\u00f1\u00f3z-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor Manuel","family":"Rosales-Don Pablo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2012.10.010_bib0005","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/archinte.1988.00380070117028","article-title":"Rhupus syndrome","volume":"148","author":"Panush","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.reuma.2012.10.010_bib0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3899\/jrheum.081067","article-title":"Overlap between systemic lupus erythematosus and rhematoid arthritis: is real or just an illusion?","volume":"36","author":"Amezcua-Guerra","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2012.10.010_bib0015","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1191\/0961203302lu189oa","article-title":"Clinical and inmunogenetic characterization or Mexican patients with rhupus","volume":"11","author":"Simon","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.reuma.2012.10.010_bib0020","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s10067-005-1149-y","article-title":"Lupus arthropathy: a case series of patients with rhupus","volume":"25","author":"Fernandez","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reuma.2012.10.010_bib0025","first-page":"8R144","article-title":"Presence of antibodies against cyclic citrullinated peptides in patients with \u00abrhupus\u00bb: a cross \u2013sectional study","author":"Amezcua-Guerra","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reuma.2012.10.010_bib0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.reuma.2010.12.006","article-title":"Rhupus: descripci\u00f3n de 4 casos","volume":"7","author":"Benavente","year":"2011","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reuma.2012.10.010_bib0035","doi-asserted-by":"crossref","first-page":"465898","DOI":"10.1155\/2010\/465898","article-title":"Anti-TNF-alpha therapies in systemic lupus erythematosus","volume":"2010","author":"Zhu","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.reuma.2012.10.010_bib0040","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/rheumatology\/kep270","article-title":"Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients","volume":"48","author":"Aringer","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reuma.2012.10.010_bib0045","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1517\/14740338.7.4.411","article-title":"Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus","volume":"7","author":"Aringer","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.reuma.2012.10.010_bib0050","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2012.10.010_bib0055","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2012.10.010_bib0060","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus the randomized, double-blind. Phase II\/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial","volume":"62","author":"Merril","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2012.10.010_bib0065","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1177\/0961203310395802","article-title":"Assessment of flares in lupus patients enrolled in a phase ii\/iiistudy of rituximab (EXPLORER)","volume":"20","author":"Merril","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.reuma.2012.10.010_bib0070","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2012.10.010_bib0075","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10067-010-1387-5","article-title":"Off-label use of rituximab in systemic lupus erythematosus: a systematic review","volume":"29","author":"Murray","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reuma.2012.10.010_bib0080","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/0961203309106174","article-title":"Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases","volume":"18","author":"Ramos-Casals","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.reuma.2012.10.010_bib0085","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/art.27541","article-title":"Safety and efficacy of rituximab in systemic lupus erythematosus. Results from 136 patients from the French AutoImmunity and Rituximab Registry","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2012.10.010_bib0090","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"35","author":"Fransen","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.reuma.2012.10.010_bib0095","first-page":"111","article-title":"\u00bfCu\u00e1l es la definici\u00f3n de rhupus?","volume":"16","author":"Simon","year":"2001","journal-title":"Rev Mex Reum"},{"key":"10.1016\/j.reuma.2012.10.010_bib0100","first-page":"47","article-title":"Erosive arthropaty: clinical variance in lupus erythematosus and association whit anti-CCP case series an review of the literature","volume":"25","author":"Martinez","year":"2007","journal-title":"Clin Exp Rheum"},{"key":"10.1016\/j.reuma.2012.10.010_bib0105","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/ard.57.9.540","article-title":"Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus","volume":"57","author":"Van Vugt","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2012.10.010_bib0110","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.reuma.2009.11.004","article-title":"Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations. A randomized and multicenter study","volume":"6","author":"Andrade-Ortega","year":"2010","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reuma.2012.10.010_bib0115","unstructured":"Houssiau FA, on behalf of European Working Party on Systemic Lupus Erythematosus Lupus Nephritis Trial Network. RING: rituximab for lupus nephritis with remission as a goal. NCT01673295 [consultado 6 Oct 2012]. Disponible en: www.ClinicalTrials.gov"},{"key":"10.1016\/j.reuma.2012.10.010_bib0120","first-page":"47","article-title":"Erosive arthropathy: clinical variance in lupus erythematosus and association with anti-CCP case series and review of the literature","volume":"25","author":"Martinez","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reuma.2012.10.010_bib0125","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/0961203307087613","article-title":"Anti-citrullinated peptide antibodies in lupus patients with or without deforming arthropathy","volume":"17","author":"Dami\u00e1n","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.reuma.2012.10.010_bib0130","first-page":"77","article-title":"Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC class II alleles in systemic lupus erythematosus","volume":"35","author":"Chan","year":"2008","journal-title":"J Rheumatol"}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X13000028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X13000028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T03:15:36Z","timestamp":1564629336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X13000028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1699258X13000028"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2012.10.010","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}